Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Sponsor: Novartis Pharmaceuticals
Summary
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Official title: A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Key Details
Gender
All
Age Range
18 Years - 100 Years
Study Type
INTERVENTIONAL
Enrollment
166
Start Date
2015-03-06
Completion Date
2027-02-10
Last Updated
2025-11-10
Healthy Volunteers
No
Interventions
IDH305
Locations (16)
Dana Farber Cancer Institute SC (1)
Boston, Massachusetts, United States
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Columbia University Medical Center- New York Presbyterian Onc Dept.
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Uni Of TX MD Anderson Cancer Cntr
Houston, Texas, United States
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Parkville, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Toronto, Ontario, Canada
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Jena, Thuringia, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Rotterdam, South Holland, Netherlands
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55
Rotterdam, Netherlands
Novartis Investigative Site
Singapore, Singapore
Novartis Investigative Site
Barcelona, Catalonia, Spain